Clinical Trials Directory

Trials / Unknown

UnknownNCT05686343

Hemodynamically Important Patent Ductus Arteriosus in Newborns Under 32 Weeks

Hemodynamically Important PDA in Newborns Under 32 Weeks: Clinical and Echocardiographic Findings and Outcomes

Status
Unknown
Phase
Study type
Observational
Enrollment
70 (estimated)
Sponsor
Ankara University · Academic / Other
Sex
All
Age
1 Minute – 7 Days
Healthy volunteers

Summary

To define the characteristics of hemodynamically significant PDA by echocardiography, to investigate the systemic effects of the ductus with cerebral and renal Doppler flow studies, and to determine the oxygen consumption in the cerebral tissue with NIRS in newborns below 32 weeks of age with PDA.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTEchocardiography, Doppler ultrasonography, Near-infrared spectroscopyEcocardiography at 1st, 3rd and 7th day of life Doppler US (cranial and renal) at 1st, 3rd and 7th day of life Near-infrared spectroscopy monitoring after birth during first 3-days of life

Timeline

Start date
2022-07-01
Primary completion
2023-07-01
Completion
2023-07-01
First posted
2023-01-17
Last updated
2023-01-17

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT05686343. Inclusion in this directory is not an endorsement.

Hemodynamically Important Patent Ductus Arteriosus in Newborns Under 32 Weeks (NCT05686343) · Clinical Trials Directory